為什麼腫瘤首次人體試驗在開始前就可能失敗
關於場地組合、方案假設、啟動延遲和隱藏執行風險的觀點。
洞察
早期腫瘤開發中，哪些訊號值得先看？
這裡整理公開研究、腫瘤會議訊號和我們對 FIH 執行風險的觀點。Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方來源會作為可篩選的資訊補充，所有卡片保留原始公開連結。
重点观点
先看那些申办方通常发现得太晚的问题。
这些固定主题让洞察页先有清楚判断：外部公开来源能同步时作为补充，不能同步时页面也不会变成空的信息库。
場地級啟動風險與傳統可行性評估
為什麼平均值和聲譽型專家選擇可能錯過真正重要的執行尾部風險。
中國創新藥如何進入全球開發語境
全球開發策略、區域選擇和試驗設計如何影響中國以外市場的可信度。
腫瘤場地選擇應如何按機制區分
ADC、雙抗、KRAS、CAR-T、放射性配體、DDR 資產和 TKI 不應使用同一套場地邏輯。
公開資訊庫
公開研究與腫瘤會議訊號
把 Apex AI 公開研究索引和 ASCO、ESMO、AACR、SITC 等官方公開來源放在同一個列表裡。可按來源、主題和關鍵詞篩選；所有卡片只保留公開後設資料和官方原始連結。
當前來源：全部來源 · 主題：AACR · 17 條 · 每頁 10 條
Men May Be More Likely Than Women to Receive Later-stage Diagnoses for Many Cancer Types in the United States
Researchers say the study’s findings, published in Cancer Epidemiology, Biomarkers & Prevention, could provide insight into the discrepancies in cancer outcomes between men and women. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
AACR Statement and Call to Action Concerning OMB Proposal to Rewrite the Rules for Scientists and Physicians Who Are Improving Pu...
The American Association for Cancer Research (AACR) is deeply concerned that the recent action of the White House Office of Management and Budget (OMB) to propose a new set of regulations on how federal grants... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
AACR Names Matthew Vander Heiden, MD, PhD, FAACR, as Editor-in-Chief of the Journal Cancer Discovery
The American Association for Cancer Research (AACR) has appointed Matthew Vander Heiden, MD, PhD, FAACR, as editor-in-chief of Cancer Discovery. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源
AACR Releases Cancer Disparities Progress Report 2026
The report features latest statistics, including promising signs of progress, and 10 compelling personal stories. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Adding a Lower Cutoff Value for CA19-9 May Identify Additional High-risk Cases of Pancreatic Cancer
CA19-9 is a biomarker whose levels often correlate with pancreatic cancer stage and prognosis, according to a study published in Clinical Cancer Research. OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源AACR CEO Margaret Foti, PhD, MD (hc): Thank you for an incredible AACR Annual Meeting 2026! - AACR Annual Meeting News
The AACR Annual Meeting 2026 featured a spectacular display of the progress that is being made against cancer due to your tremendous efforts. All of you—cancer researchers, clinicians, other health care profes... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Emerging Frontiers in Oncology to Support AACR and Early-Career Investigators Through Annual Oncology Summit
The American Association for Cancer Research (AACR) today thanked Emerging Frontiers in Oncology (EFO) for its support of the cancer research workforce through fundraising associated with the 8th Annual Emergi... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Closing Plenary Session examined highlights from the AACR Annual Meeting 2026 - AACR Annual Meeting News
Katerina A. Politi, PhD, identified takeaways emerging from presentations in basic and translational science, including that fundamental insights into cancer biology are revealing new strategies to treat cance... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Fifth Plenary Session spotlighted new treatment modalities transforming the oncology landscape - AACR Annual Meeting News
Katayoun Rezvani, MD, PhD, chaired the session, which shone a light on radiopharmaceuticals, next-generation biologics, and cellular immunotherapy as groundbreaking therapeutic modalities for cancer, with a fo... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源Final New Drugs on the Horizon session completed the series with the last four novel molecules - AACR Annual Meeting News
Presenters described a first-in-class inhibitor of cyclin A/B-substrate interaction, a molecular glue degrader for the treatment of acute myeloid leukemia, a novel antibody-drug conjugate, and a dual T-cell ag... OncoLattice flags this public source because it may inform oncology trial timing, competitor movement, site strategy, or development positioning.
檢視官方來源